Compare MOH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | TGTX |
|---|---|---|
| Founded | 1980 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.5B |
| IPO Year | 2002 | 2008 |
| Metric | MOH | TGTX |
|---|---|---|
| Price | $196.74 | $55.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $209.12 | $69.71 |
| AVG Volume (30 Days) | 547.3K | ★ 1.6M |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 1.46 | 0.17 |
| Revenue | ★ $45,426,000,000.00 | $2,785,000.00 |
| Revenue This Year | $2.05 | $55.81 |
| Revenue Next Year | $8.06 | $37.36 |
| P/E Ratio | ★ $134.14 | $313.76 |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $26.76 |
| 52 Week High | $244.89 | $59.30 |
| Indicator | MOH | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 51.25 |
| Support Level | $196.50 | $51.76 |
| Resistance Level | $204.11 | $58.26 |
| Average True Range (ATR) | 6.54 | 2.04 |
| MACD | 0.88 | -0.36 |
| Stochastic Oscillator | 73.00 | 49.73 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.